Smith & Nephew SNATS Current Ratio 2006-2018 | SNN

Current and historical current ratio for Smith & Nephew SNATS (SNN) from 2006 to 2018. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Smith & Nephew SNATS current ratio for the three months ending December 31, 2018 was 0.00.
Smith & Nephew SNATS Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2018-12-31 $3.08B $1.47B 2.10
2018-06-30 $2.66B $1.25B 2.13
2017-12-31 $2.73B $1.35B 2.03
2017-06-30 $2.58B $1.19B 2.18
2016-12-31 $2.53B $1.35B 1.88
2015-12-31 $2.48B $1.34B 1.84
2015-06-30 $2.43B $1.23B 1.99
2014-12-31 $2.44B $1.16B 2.10
2014-09-30 $2.53B $1.23B 2.06
2014-06-30 $2.53B $1.15B 2.21
2014-03-31 $2.39B $1.06B 2.25
2013-12-31 $2.26B $1.07B 2.10
2013-09-30 $2.17B $1.03B 2.11
2013-06-30 $2.08B $0.89B 2.34
2013-03-31 $2.07B $0.92B 2.26
2012-12-31 $2.14B $0.93B 2.31
2012-09-30 $2.29B $0.91B 2.52
2012-06-30 $2.09B $0.80B 2.62
2012-03-31 $2.32B $1.03B 2.26
2011-12-31 $2.21B $1.14B 1.94
2011-09-30 $2.22B $1.29B 1.73
2011-06-30 $2.24B $1.35B 1.66
2011-03-31 $2.21B $0.88B 2.51
2010-12-31 $2.15B $0.91B 2.36
2010-09-30 $2.35B $0.86B 2.72
2010-06-30 $2.15B $0.78B 2.75
2010-03-31 $2.09B $0.88B 2.38
2009-12-31 $2.09B $0.86B 2.42
2009-09-30 $2.15B $0.91B 2.37
2009-06-30 $2.09B $0.88B 2.38
2009-03-31 $2.00B $1.00B 2.00
2008-12-31 $1.99B $0.97B 2.05
2008-09-30 $1.98B $1.04B 1.90
2008-06-30 $2.06B $2.50B 0.83
2008-03-31 $2.01B $2.51B 0.80
2007-12-31 $1.91B $2.27B 0.84
2007-09-30 $1.80B $2.01B 0.90
2007-06-30 $1.77B $1.75B 1.01
2007-03-31 $1.64B $0.83B 1.97
2006-12-31 $1.65B $0.82B 2.02
2006-09-30 $1.65B $0.90B 1.83
2006-06-30 $1.70B $0.89B 1.91
2006-03-31 $1.67B $0.95B 1.77
2005-12-31 $1.71B $1.07B 1.59
2005-09-30 $1.35B $0.99B 1.36
2005-06-30 $1.36B $0.99B 1.38
2005-03-31 $1.38B $0.98B 1.40
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $16.746B $4.904B
Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physicianadvantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment todeliver new levels of healing to patients throughout the world
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $134.809B 26.28
Medtronic (MDT) Ireland $114.856B 16.79
Stryker (SYK) United States $69.039B 24.64
Boston Scientific (BSX) United States $49.279B 23.63
Baxter (BAX) United States $38.988B 25.01
Zimmer Biomet Holdings (ZBH) United States $25.460B 16.29
Canopy Growth (CGC) Canada $16.646B 0.00
ResMed (RMD) United States $14.578B 27.64
Aurora Cannabis (ACB) Canada $9.230B 65.07
Bio-Rad Laboratories (BIO) United States $8.754B 50.22
Perrigo (PRGO) Ireland $6.685B 10.84
Hill-Rom Holdings (HRC) United States $6.417B 19.85
Insulet (PODD) United States $4.971B 1666.40
GW Pharmaceuticals (GWPH) United Kingdom $4.857B 0.00
ICU Medical (ICUI) United States $4.694B 29.07
Haemonetics (HAE) United States $4.319B 38.31
Hutchison China MediTech (HCM) China $3.951B 0.00
Agios Pharmaceuticals (AGIO) United States $3.335B 0.00
NuVasive (NUVA) United States $3.048B 26.48
Neogen (NEOG) United States $3.014B 49.01
Quidel (QDEL) United States $2.477B 22.16
National Vision Holdings (EYE) United States $2.284B 44.94
Aphria (APHA) $1.955B 0.00
HEXO (HEXO) $1.502B 0.00
Phibro Animal Health (PAHC) United States $1.342B 19.28
VAREX IMAGING (VREX) United States $1.234B 24.16
Cardiovascular Systems (CSII) United States $1.222B 877.50
AtriCure (ATRC) United States $1.081B 0.00
Lantheus Holdings (LNTH) United States $0.962B 26.00
Omeros (OMER) United States $0.930B 0.00
PetIQ (PETQ) United States $0.874B 25.02
Cerus (CERS) United States $0.826B 0.00
MacroGenics (MGNX) United States $0.805B 0.00
NanoString Technologies (NSTG) United States $0.759B 0.00
Evolus (EOLS) United States $0.721B 0.00
Eagle Pharmaceuticals (EGRX) United States $0.720B 24.51
TG Therapeutics (TGTX) United States $0.706B 0.00
OraSure Technologies (OSUR) United States $0.596B 25.95
Surmodics (SRDX) United States $0.585B 85.02
LeMaitre Vascular (LMAT) United States $0.554B 26.32
Meridian Bioscience (VIVO) United States $0.551B 16.42
Quanterix (QTRX) United States $0.500B 0.00
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.344B 0.00
Insys Therapeutics (INSY) United States $0.321B 0.00
Utah Medical Products (UTMD) United States $0.319B 20.75
BioLife Solutions (BLFS) United States $0.308B 127.08
Vapotherm (VAPO) United States $0.283B 0.00
Rockwell Medical (RMTI) United States $0.263B 0.00
Cytosorbents (CTSO) United States $0.223B 0.00
Owens & Minor (OMI) United States $0.214B 2.93
Zynex (ZYXI) United States $0.175B 18.69
Bovie Medical (APYX) United States $0.149B 0.00
Chimerix (CMRX) United States $0.129B 0.00
Fonar (FONR) United States $0.128B 6.85
Chembio Diagnostics (CEMI) United States $0.123B 0.00
Surface Oncology (SURF) United States $0.112B 0.00
United-Guardian (UG) United States $0.088B 20.27
Female Health (VERU) United States $0.086B 0.00
InfuSystems Holdings (INFU) United States $0.083B 0.00
Neurotrope (NTRP) United States $0.076B 0.00
Trinity Biotech (TRIB) Ireland $0.067B 19.86
Oramed Pharmaceuticals (ORMP) United States $0.066B 0.00
GUARDION HEALTH (GHSI) United States $0.049B 0.00
ImmuCell (ICCC) United States $0.044B 0.00
Senestech (SNES) United States $0.035B 0.00
Valeritas Holdings (VLRX) United States $0.030B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.025B 0.00
Myomo (MYO) United States $0.021B 0.00
Capricor Therapeutics (CAPR) United States $0.017B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.014B 0.00
Cellectar Biosciences (CLRB) United States $0.013B 0.00
Akers Biosciences Inc (AKER) United States $0.010B 0.00
NeuroMetrix (NURO) United States $0.007B 12.64